Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,951 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Utility of immunohistochemistry with an antibody against MYC at the initial diagnosis of follicular lymphoma, grade 3A, for predicting a more aggressive clinical course: a case report and review of the literature.
Ichikawa K, Aritaka N, Ogura K, Hosone M, Ota Y, Sato E, Komatsu N, Hirano T. Ichikawa K, et al. Among authors: sato e. Int J Clin Exp Pathol. 2015 Jun 1;8(6):7559-64. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 26261669 Free PMC article. Review.
Incidences and outcomes of therapy-related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: Surveillance of the CML Cooperative Study Group.
Iriyama N, Tokuhira M, Takaku T, Sato E, Ishikawa M, Nakazato T, Sugimoto KJ, Fujita H, Fujioka I, Hatta Y, Kizaki M, Komatsu N, Asou N, Kawaguchi T. Iriyama N, et al. Among authors: sato e. Leuk Res. 2017 Mar;54:55-58. doi: 10.1016/j.leukres.2017.01.003. Epub 2017 Jan 5. Leuk Res. 2017. PMID: 28109974
Introduction of second-generation tyrosine kinase inhibitors may reduce the prognostic impact of high-risk patients, according to the European treatment and outcome study (EUTOS) score.
Sato E, Iriyama N, Tokuhira M, Takaku T, Ishikawa M, Nakazato T, Sugimoto KJ, Fujita H, Fujioka I, Asou N, Komatsu N, Kizaki M, Hatta Y, Kawaguchi T. Sato E, et al. Leuk Lymphoma. 2018 May;59(5):1105-1112. doi: 10.1080/10428194.2017.1365858. Epub 2017 Aug 25. Leuk Lymphoma. 2018. PMID: 28838287
Clinical Efficacy and Safety of First-Line Dasatinib Therapy and the Relevance of Velocity of BCR-ABL1 Transcript Decline for Achievement of Molecular Responses in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Report from the Juntendo Yamanashi Cooperative Study Group.
Takaku T, Iriyama N, Mitsumori T, Sato E, Gotoh A, Kirito K, Noguchi M, Koike M, Sakamoto J, Oba K, Komatsu N. Takaku T, et al. Among authors: sato e. Oncology. 2018;94(2):85-91. doi: 10.1159/000481945. Epub 2017 Nov 18. Oncology. 2018. PMID: 29151104
1,951 results